NCNA
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Aug 8 closing price
Capitalization
12.29M
NERV
Price
$1.76
Change
-$0.04 (-2.22%)
Updated
Aug 8 closing price
Capitalization
12.31M
2 days until earnings call
Interact to see
Advertisement

NCNA vs NERV

Header iconNCNA vs NERV Comparison
Open Charts NCNA vs NERVBanner chart's image
NuCana
Price$0.03
Change-$0.00 (-0.00%)
Volume$179.3M
Capitalization12.29M
Minerva Neurosciences
Price$1.76
Change-$0.04 (-2.22%)
Volume$905
Capitalization12.31M
NCNA vs NERV Comparison Chart in %
Loading...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.78B. The market cap for tickers in the group ranges from 58 to 93.98B. VRTX holds the highest valuation in this group at 93.98B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 13%. SPRBD experienced the highest price growth at 9,061%, while BIVI experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was -60% and the average quarterly volume growth was 87%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -14 (-100 ... +100)

Market Cap

The average market capitalization across the group is 12.3M. The market cap for tickers in the group ranges from 12.29M to 12.31M. NERV holds the highest valuation in this group at 12.31M. The lowest valued company is NCNA at 12.29M.

High and low price notable news

The average weekly price growth across all stocks in the group was -13%. For the same group, the average monthly price growth was -22%, and the average quarterly price growth was -59%. NERV experienced the highest price growth at -8%, while NCNA experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the group was -11%. For the same stocks of the group, the average monthly volume growth was -74% and the average quarterly volume growth was 690,275%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 69
P/E Growth Rating: 99
Price Growth Rating: 79
SMR Rating: 100
Profit Risk Rating: 100
Seasonality Score: -2 (-100 ... +100)
VS
NCNA vs. NERV commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NCNA is a StrongBuy and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (NCNA: $0.03 vs. NERV: $1.76)
Brand notoriety: NCNA and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NCNA: 99% vs. NERV: 7%
Market capitalization -- NCNA: $12.29M vs. NERV: $12.31M
NCNA [@Biotechnology] is valued at $12.29M. NERV’s [@Biotechnology] market capitalization is $12.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileNCNA’s FA Score has 0 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • NCNA’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than NCNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NCNA’s TA Score shows that 3 TA indicator(s) are bullish while NERV’s TA Score has 2 bullish TA indicator(s).

  • NCNA’s TA Score: 3 bullish, 3 bearish.
  • NERV’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NCNA is a better buy in the short-term than NERV.

Price Growth

NCNA (@Biotechnology) experienced а -17.65% price change this week, while NERV (@Biotechnology) price change was -7.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was +6.85%, and the average quarterly price growth was +13.24%.

Reported Earning Dates

NERV is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+0.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NCNA($12.3M) and NERV($12.3M) have the same market capitalization . NERV YTD gains are higher at: -20.778 vs. NCNA (-97.294). NERV has higher annual earnings (EBITDA): 8.58M vs. NCNA (-16.98M). NERV has more cash in the bank: 17.3M vs. NCNA (3.95M). NERV has less debt than NCNA: NERV (0) vs NCNA (173K). NCNA (0) and NERV (0) have equivalent revenues.
NCNANERVNCNA / NERV
Capitalization12.3M12.3M100%
EBITDA-16.98M8.58M-198%
Gain YTD-97.294-20.778468%
P/E RatioN/A2.15-
Revenue00-
Total Cash3.95M17.3M23%
Total Debt173K0-
FUNDAMENTALS RATINGS
NERV vs NCNA: Fundamental Ratings
NERV
NCNA
OUTLOOK RATING
1..100
8964
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6197
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
4650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (40) in the Biotechnology industry is somewhat better than the same rating for NCNA (99). This means that NERV’s stock grew somewhat faster than NCNA’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NCNA (100). This means that NERV’s stock grew similarly to NCNA’s over the last 12 months.

NERV's SMR Rating (100) in the Biotechnology industry is in the same range as NCNA (100). This means that NERV’s stock grew similarly to NCNA’s over the last 12 months.

NERV's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for NCNA (97). This means that NERV’s stock grew somewhat faster than NCNA’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as NCNA (100). This means that NERV’s stock grew similarly to NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NCNANERV
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 20 days ago
79%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WATT0.290.01
+2.25%
Energous Corp
LTRX2.990.02
+0.67%
Lantronix
BSBR4.960.01
+0.20%
Banco Santander (Brasil) SA
APLS24.370.04
+0.16%
Apellis Pharmaceuticals

NCNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been closely correlated with RNAC. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-1.83%
RNAC - NCNA
93%
Closely correlated
-0.09%
AGEN - NCNA
93%
Closely correlated
N/A
TAOX - NCNA
92%
Closely correlated
+3.53%
ALLR - NCNA
86%
Closely correlated
-1.66%
NRXP - NCNA
85%
Closely correlated
+2.44%
More

NERV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DNLI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-1.98%
DNLI - NERV
34%
Loosely correlated
-1.90%
ANAB - NERV
33%
Poorly correlated
+3.24%
IDYA - NERV
32%
Poorly correlated
+3.08%
MLTX - NERV
31%
Poorly correlated
+0.98%
GBIO - NERV
31%
Poorly correlated
-1.20%
More